Tirzepatide raised the bar with dual-receptor action
Market Report Scope GLP-1 Receptor Agonist Market Report Coverage Uncover macros and micros vetted on 75+ parameters: Get instant access to report GLP-1 Receptor Agonist Industry News In July 2025, PolyPid Ltd
Others sidestep the needle and deliver the drug in pill form
Importantly, treatment with retatrutide meaningfully reduced certain cardiovascular risk factors, with the highest dose (12mg) delivering average reductions of 37% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 7.5 in (19.0 cm) in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP) in the TRIUMPH-3 study
Weight Loss For individuals living with obesity, weight loss outcomes in early trials consistently exceeded expectations
Its important to note that GLP-1 medications are not recommended for individuals with a history of certain thyroid cancers or pancreatitis, as studies have shown potential risks in these cases
